DexCom, Inc. (DXCM) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
DXCM price how computed
Forward Fair Value verdict
UndervaluedDXCM is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $84.11
- Sector
- Healthcare
- 12-month range
- $54.84–$92.34
- Market cap
- $31.7B
- From 52-week high
- -8.9%
- Shares outstanding
- 377M
- Rank in Healthcare by discount to fair value
- #13 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
DexCom, Inc. manufactures and distributes continuous glucose monitoring systems designed to help people with diabetes track their blood sugar levels in real time. The company operates globally, serving patients in multiple countries through its glucose monitoring technology and related products.
DXCM currently ranks #13 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $31.7B
- P/E (trailing)
- 33x
- Revenue (TTM)
- $4.97B
- Net margin
- 20.1%
- EPS (TTM)
- $2.55
- Gross margin
- 63.4%
- Debt / equity
- 0.53
- Revenue growth (3-yr avg)
- 11.4%
- Shares outstanding
- 377M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 48 · neutral
- 50-day average
- $87.55
- 200-day average
- $73.97
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+14.8%)
2026-03 ▲ beat (+19.1%)
2025-12 ▲ beat (+4.6%)
2025-09 ▲ beat (+7.0%)
2025-06 ▲ beat (+9.1%)
2025-03 ▼ miss (-3.0%)
2024-12 ▼ miss (-10.0%)
2024-09 ▲ beat (+4.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 25 buy · 3 hold · 0 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $96.2
- Target vs last price
- +14.4%
What our data shows for DXCM
- Our model validated 12 trailing price-to-earnings windows for DXCM, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $54.84–$92.34.
- The 14-day relative strength index sits at a neutral 48.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for DXCM
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent DXCM news
TickrTrends' derived news-sentiment signal for DXCM is currently leaning positive, computed from recent coverage.
- DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors (gurufocus.com, 2026-10-21)
TickrTrends take: DexCom shares experienced a decline, yet the company maintains a strong GF Score of 95, which reflects substantial fundamental quality across its operations in the Healthcare sector. TickrTrends currently identifies DXCM as undervalued, suggesting that recent share weakness may present an opportunity for investors focused on valuation relative to business quality. A valuation-focused reader should monitor whether the company's fundamentals remain intact following this price movement, as the disconnect between valuation assessment and recent share performance could indicate market sentiment has shifted away from underlying business strength. - DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on October 21, 2026 (gurufocus.com, 2026-10-21)
TickrTrends take: DexCom's stock decline on October 21, 2026, occurred while broader markets advanced, suggesting sector-specific or company-specific pressure that diverged from overall market momentum. TickrTrends currently identifies DXCM as undervalued within the Healthcare sector, which may present an opportunity for investors if the recent share weakness reflects temporary headwinds rather than fundamental deterioration. Valuation-focused observers should monitor whether this pullback continues or stabilizes, as the undervalued designation would need reassessment if negative catalysts prove persistent. - DXCM Maintains Buy Rating by BTIG -- Price Target Raised to $96.00 (gurufocus.com, 2026-10-12)
TickrTrends take: BTIG's maintained buy rating and raised price target of $96 align with TickrTrends' assessment that DXCM is currently undervalued in the Healthcare sector, suggesting analyst confidence in the company's fundamental prospects. A valuation-focused reader should monitor whether the stock price movement toward the $96 target occurs alongside earnings performance and whether the market eventually reprices the company to close any valuation gap that currently exists. The combination of sustained analyst support and an undervalued designation indicates potential for convergence between current trading levels and fair value.
More DXCM news
- Dexcom Launches Largest Dexcom U Program Season Yet, Supporting College Athletes with Diabetes (DXCM) (gurufocus.com, 2026-10-06)
- DXCM Maintains by RBC Capital -- Price Target Raised to $105 (gurufocus.com, 2026-10-01)
What people are saying
Follow the DXCM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for DXCM show improvement this week despite a shift in trend dynamics. The 50/200-day trend state moved from uptrend to mixed, while the quality grade advanced from B to A, reflecting enhanced operational or financial metrics. With a current valuation verdict of undervalued, the stock presents characteristics that warrant monitoring.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — DXCM's 50/200-day trend state improved from mixed to uptrend this week, while its sector discount rank shifted from number 19 to number 24, indicating a relative decline in valuation positioning within the Healthcare sector. Despite this ranking decline, DXCM remains assessed as undervalued according to TickrTrends' current valuation verdict.
- 2026-09-21 — DXCM has experienced notable shifts in its derived indicators this week. The 50/200-day trend state transitioned from uptrend to mixed conditions, while momentum indicators moved from a B rating to none, and the RSI zone shifted from oversold to neutral territory. The stock currently carries an undervalued verdict according to TickrTrends' valuation assessment.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is DXCM stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), DXCM is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is DXCM's TickrTrends verdict?
DXCM's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does DXCM compare to other Healthcare stocks?
DXCM ranks #13 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is DXCM overbought or oversold?
DXCM's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does DXCM report earnings next?
DXCM's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does DXCM usually beat earnings estimates?
Over its last 8 reported quarters DXCM beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DXCM?
Of 28 analysts covering DXCM, 25 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $96.2 (+14.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
DXCM vs COO · DXCM vs EMBC · DXCM vs HQY · DXCM vs INDV · DXCM vs LFST